{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:44:14Z","timestamp":1794491054661,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014989","name":"Chan Zuckerberg Initiative","doi-asserted-by":"publisher","award":["DAF 2022-316467"],"award-info":[{"award-number":["DAF 2022-316467"]}],"id":[{"id":"10.13039\/100014989","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Rare Disease Research Alliance","award":["101156595"],"award-info":[{"award-number":["101156595"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Individualized medicine has the potential to be a transformative approach to healthcare that tailors medical treatments to the unique makeup of each patient. This report explores the potential of individualized genetic medicines to meet the pressing need for effective treatments for individuals with rare genetic diseases, and funding models to support these treatments. Although recent successes have been achieved, significant administrative and financial challenges remain in implementing individualized treatment trials. This report investigates funding associated with such therapeutics. Funding challenges, key strategic operational factors, potential payor support, historic funding models, and ethical elements ultimately leading to financial support of patient treatment are considered. By addressing these questions, this report aims to provide an overview of the complex issues surrounding individualized medicine, offering insights into balancing its promises with practical and ethical considerations as the field and associated funding models continue to evolve.<\/jats:p>","DOI":"10.1186\/s13023-026-04388-1","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:37:12Z","timestamp":1779385032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies"],"prefix":"10.1186","volume":"21","author":[{"given":"Nicole","family":"Nolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Caneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis R.","family":"Coughlin II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot A.","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Douthwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm","family":"Graessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Kim-McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Kuniholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Martinsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Meserve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Booma","family":"Yandava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5799-9492","authenticated-orcid":false,"given":"Roger J.","family":"Paxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"1","key":"4388_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","volume":"24","author":"AH Jonker","year":"2025","unstructured":"Jonker AH, Tataru EA, Graessner H, Dimmock D, Jaffe A, Baynam G, et al. The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nat Rev Drug Discov. 2025;24(1):40\u201356.","journal-title":"Nat Rev Drug Discov"},{"key":"4388_CR2","doi-asserted-by":"crossref","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2).","DOI":"10.3390\/ijms18020441"},{"issue":"5","key":"4388_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u20138.","journal-title":"J Med Genet"},{"key":"4388_CR4","doi-asserted-by":"crossref","unstructured":"Fischer A, Hacein-Bey-Abina S. Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med. 2020;217(2).","DOI":"10.1084\/jem.20190607"},{"issue":"4","key":"4388_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","volume":"104","author":"ML Hu","year":"2021","unstructured":"Hu ML, Edwards TL, O\u2019Hare F, Hickey DG, Wang JH, Liu Z, et al. Gene therapy for inherited retinal diseases: progress and possibilities. Clin Exp Optom. 2021;104(4):444\u201354.","journal-title":"Clin Exp Optom"},{"key":"4388_CR6","doi-asserted-by":"crossref","unstructured":"Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci. 2023;24(15).","DOI":"10.3390\/ijms241511939"},{"issue":"3","key":"4388_CR7","first-page":"194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK, Nusinersen. A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. J Pediatr Pharmacol Ther. 2019;24(3):194\u2013203.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"4388_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","volume":"6","author":"AM Keeler","year":"2019","unstructured":"Keeler AM, Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? Annu Rev Virol. 2019;6(1):601\u201321.","journal-title":"Annu Rev Virol"},{"key":"4388_CR9","doi-asserted-by":"publisher","first-page":"101875","DOI":"10.1016\/j.gimo.2024.101875","volume":"2","author":"H Lesmana","year":"2024","unstructured":"Lesmana H, Kim SY, Corado AM, Poskanzer SA. *documents@acmg.net ATC. Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOC): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genet Med Open. 2024;2:101875.","journal-title":"Genet Med Open"},{"key":"4388_CR10","unstructured":"Bock E. Rare Diseases Are a Public Health Issue. Available from: https:\/\/nihrecord.nih.gov\/2021\/04\/16\/rare-diseases-are-public-health-issue."},{"key":"4388_CR11","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus ADM, Le Cam Y. Orphan medicine incentives: how to address the unmet needs of rare disease patients by optimizing the european orphan medicinal product landscape guiding principles and policy proposals by the european expert group for orphan drug incentives (OD expert group). Front Pharmacol. 2021;12.","DOI":"10.3389\/fphar.2021.744532"},{"issue":"1","key":"4388_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A, Collaborative N. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med (Lond). 2024;4(1):6.","journal-title":"Commun Med (Lond)"},{"issue":"17","key":"4388_CR13","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med. 2019;381(17):1644\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"4388_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran H, Moazami MP, Yang H, McKenna-Yasek D, Douthwright CL, Pinto C, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2022;28(1):117\u201324.","journal-title":"Nat Med"},{"key":"4388_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VALA Korobeynikov","year":"2022","unstructured":"Korobeynikov VALA, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28:104\u201316.","journal-title":"Nat Med"},{"issue":"1","key":"4388_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41591-021-01629-7","volume":"28","author":"ER Lopez","year":"2022","unstructured":"Lopez ER, Borschel WF, Traynor BJ. New antisense oligonucleotide therapies reach first base in ALS. Nat Med. 2022;28(1):25\u20137.","journal-title":"Nat Med"},{"key":"4388_CR17","doi-asserted-by":"crossref","unstructured":"Augustine EF, Yu TW, Finkel RS. N-of-1 studies in an era of precision medicine. JAMA. 2024.","DOI":"10.1001\/jama.2024.14637"},{"issue":"7971","key":"4388_CR18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","volume":"619","author":"J Kim","year":"2023","unstructured":"Kim J, Woo S, de Gusmao CM, Zhao B, Chin DH, DiDonato RL, et al. A framework for individualized splice-switching oligonucleotide therapy. Nature. 2023;619(7971):828\u201336.","journal-title":"Nature"},{"issue":"7779","key":"4388_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/d41586-019-03164-5","volume":"574","author":"H Ledford","year":"2019","unstructured":"Ledford H. Super-precise new CRISPR tool could tackle a plethora of genetic diseases. Nature. 2019;574(7779):464\u20135.","journal-title":"Nature"},{"issue":"11","key":"4388_CR20","doi-asserted-by":"publisher","first-page":"e224115","DOI":"10.1001\/jamahealthforum.2022.4115","volume":"3","author":"RE Sachs","year":"2022","unstructured":"Sachs RE, Donohue JM, Dusetzina SB. Reforming Reimbursement for the US Food and Drug Administration\u2019s Accelerated Approval Program to Support State Medicaid Programs. JAMA Health Forum. 2022;3(11):e224115.","journal-title":"JAMA Health Forum"},{"issue":"10","key":"4388_CR21","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.2967\/jnumed.118.216945","volume":"59","author":"B Brown","year":"2018","unstructured":"Brown B, Ortiz C, Dube K. Assessment of the Right-to-Try Law: The Pros and the Cons. J Nucl Med. 2018;59(10):1492\u20133.","journal-title":"J Nucl Med"},{"issue":"1","key":"4388_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/1468-0009.12728","volume":"103","author":"RM Conti","year":"2025","unstructured":"Conti RM, Demartino P, Gruber J, Lo AW, Sun Y, Wu J. Innovative Insurance to Improve US Patient Access to Cell and Gene Therapy. Milbank Q. 2025;103(1):32\u201351.","journal-title":"Milbank Q"},{"key":"4388_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1146\/annurev-genom-112921-022635","volume":"23","author":"CH Halbert","year":"2022","unstructured":"Halbert CH. Equity in Genomic Medicine. Annu Rev Genomics Hum Genet. 2022;23:613\u201325.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"1","key":"4388_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11606-020-06064-x","volume":"36","author":"E Chapman-Davis","year":"2021","unstructured":"Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, et al. Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center. J Gen Intern Med. 2021;36(1):35\u201342.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"4388_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cpt.2471","volume":"111","author":"HG Eichler","year":"2022","unstructured":"Eichler HG, Trusheim M, Schwarzer-Daum B, Larholt K, Zeitlinger M, Brunninger M, et al. Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict. Clin Pharmacol Ther. 2022;111(1):52\u201362.","journal-title":"Clin Pharmacol Ther"},{"key":"4388_CR26","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41591-024-03071-x","volume":"30","author":"JMYON Pian","year":"2024","unstructured":"Pian JMYON, Vitarello J, Yan WX, Lo AW, Yu TW. How to pay for individualized genetic medicines. Nat Med. 2024;30:1816\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"4388_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/nat.2021.0046","volume":"32","author":"ST Crooke","year":"2022","unstructured":"Crooke ST. Addressing the Needs of Patients with Ultra-Rare Mutations One Patient at a Time: The n-Lorem Approach. Nucleic Acid Ther. 2022;32(2):95\u2013100.","journal-title":"Nucleic Acid Ther"},{"key":"4388_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41587-023-01724-9","volume":"41","author":"C Seydel","year":"2023","unstructured":"Seydel C. Personalized medicine is having its day. Nat Biotechnol. 2023;41:441\u20136.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4388_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/nat.2021.0035","volume":"32","author":"A Bateman-House","year":"2022","unstructured":"Bateman-House A, Kearns L. Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses. Nucleic Acid Ther. 2022;32(2):111\u20137.","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"4388_CR30","first-page":"e2671","volume":"93","author":"R Dal-Re","year":"2020","unstructured":"Dal-Re R, Palau F, Guillen-Navarro E, Ayuso C. Participant-funded clinical trials on rare diseases. Pediatr (Engl Ed). 2020;93(4):e2671\u20139.","journal-title":"Pediatr (Engl Ed)"},{"issue":"1","key":"4388_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/medethics-2018-104966","volume":"45","author":"M King","year":"2019","unstructured":"King M, Ballantyne A. Donor-funded research: permissible, not perfect. J Med Ethics. 2019;45(1):36\u201340.","journal-title":"J Med Ethics"},{"issue":"2","key":"4388_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11019-016-9741-2","volume":"20","author":"D Shaw","year":"2017","unstructured":"Shaw D, de Wert G, Dondorp W, Townend D, Bos G, van Gelder M. Permitting patients to pay for participation in clinical trials: the advent of the P4 trial. Med Health Care Philos. 2017;20(2):219\u201327.","journal-title":"Med Health Care Philos"},{"issue":"10","key":"4388_CR33","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/s41591-021-01519-y","volume":"27","author":"PB Kane","year":"2021","unstructured":"Kane PB, Bittlinger M, Kimmelman J. Individualized therapy trials: navigating patient care, research goals and ethics. Nat Med. 2021;27(10):1679\u201386.","journal-title":"Nat Med"},{"issue":"1","key":"4388_CR34","doi-asserted-by":"publisher","first-page":"9802","DOI":"10.1038\/s41467-024-54077-5","volume":"15","author":"O Kim-McManus","year":"2024","unstructured":"Kim-McManus O, Gleeson JG, Mignon L, Smith Fine A, Yan W, Nolen N, et al. A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nat Commun. 2024;15(1):9802.","journal-title":"Nat Commun"},{"key":"4388_CR35","unstructured":"Research CfDEa. Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators: US Food and Drug Administration 2021; 2021. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or."},{"key":"4388_CR36","unstructured":"Center for Drug Evaluation R. Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators: US Food and Drug Administration; 2022. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drug."},{"issue":"2","key":"4388_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/nat.2021.0039","volume":"32","author":"M Synofzik","year":"2022","unstructured":"Synofzik M, van Roon-Mom WMC, Marckmann G, van Duyvenvoorde HA, Graessner H, Schule R, et al. Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. Nucleic Acid Ther. 2022;32(2):83\u201394.","journal-title":"Nucleic Acid Ther"},{"issue":"10","key":"4388_CR38","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1038\/s41591-024-03217-x","volume":"30","author":"R Schuele","year":"2024","unstructured":"Schuele R, Synofzik M, Graessner H, Aartsma-Rus A. Advancing ASO therapies from development to implementation. Nat Med. 2024;30(10):2725\u20136.","journal-title":"Nat Med"},{"key":"4388_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1740774515625964","volume":"13","author":"A Sertkaya","year":"2016","unstructured":"Sertkaya A, WH-H, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trails. 2016;13:117\u201326.","journal-title":"Clin Trails"},{"key":"4388_CR40","unstructured":"Deciding Whether to Be Part of a Clinical Trial. Available from: https:\/\/www.cancer.org\/cancer\/managing-cancer\/making-treatment-decisions\/clinical-trials\/what-you-need-to-know\/who-does-clinical-trials.html."},{"key":"4388_CR41","unstructured":"15 ACAIF-S. Available from: https:\/\/www.cms.gov\/CCIIO\/Resources\/Fact-Sheets-and-FAQs\/aca_implementation_faqs15."},{"issue":"20","key":"4388_CR42","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1002\/cncr.32360","volume":"125","author":"S Obeng-Gyasi","year":"2019","unstructured":"Obeng-Gyasi S, Kircher SM, Lipking KP, Keele BJ, Benson AB, Wagner LI, et al. Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape. Cancer. 2019;125(20):3488\u201393.","journal-title":"Cancer"},{"key":"4388_CR43","unstructured":"Center UDCC. Clinical Trials & Insurance. Available from: https:\/\/health.ucdavis.edu\/cancer\/clinical-trials\/are-trials-covered-by-insurance.html."},{"key":"4388_CR44","unstructured":"Caneva C. Payor Support of Individualized Therapy Patient Treatment and Care (Personal Communication). In: Paxton R, editor. 2024. pp. 1\u20132."},{"key":"4388_CR45","unstructured":"SGB 5 -. nichtamtliches Inhaltsverzeichnis. Available from: https:\/\/www.gesetze-im-internet.de\/sgb_5\/index.html."},{"key":"4388_CR46","unstructured":"Bundesverfassungsgericht - Entscheidung. finden. Available from: https:\/\/www.bundesverfassungsgericht.de\/SharedDocs\/Entscheidungen\/DE\/2005\/12\/rs20051206_1bvr034798.html."},{"key":"4388_CR47","unstructured":"KHEntgG - Einzelnorm. Available from: https:\/\/www.gesetze-im-internet.de\/khentgg\/__3.html."},{"issue":"2","key":"4388_CR48","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S1470-2045(15)00620-8","volume":"17","author":"V Prasad","year":"2016","unstructured":"Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17(2):e81\u20136.","journal-title":"Lancet Oncol"},{"key":"4388_CR49","unstructured":"NCI Funding Policy for RPG Awards FY. 2019 NCI DEA. Available from: https:\/\/deainfo.nci.nih.gov \u203a finalfundltr2019."},{"key":"4388_CR50","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1245\/s10434-024-16464-6","volume":"32","author":"MMMKM Khan","year":"2025","unstructured":"Khan MMMKM, Stecko H, Pawlik TM. Disparities in Next-Generation Genetic Sequencing Among Individuals with Cancer. Ann Surg Oncol. 2025;32:650\u20132.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"4388_CR51","doi-asserted-by":"publisher","first-page":"101221","DOI":"10.1016\/j.gim.2024.101221","volume":"26","author":"AN Talati","year":"2024","unstructured":"Talati AN, Mallampati DP, Hardisty EE, Gilmore KL, Vora NL. Disparities in access to reproductive genetic services associated with geographic location of residence and maternal race and ethnicity. Genet Med. 2024;26(11):101221.","journal-title":"Genet Med"},{"issue":"4","key":"4388_CR52","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.cell.2019.04.032","volume":"177","author":"G Sirugo","year":"2019","unstructured":"Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. Cell. 2019;177(4):1080.","journal-title":"Cell"},{"issue":"12","key":"4388_CR53","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.cell.2022.05.010","volume":"185","author":"SS Lee","year":"2022","unstructured":"Lee SS, Appelbaum PS, Chung WK. Challenges and potential solutions to health disparities in genomic medicine. Cell. 2022;185(12):2007\u201310.","journal-title":"Cell"},{"key":"4388_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/maq.12639","volume":"35","author":"N Kenworthy","year":"2021","unstructured":"Kenworthy N. Like a Grinding Stone: How Crowdfunding Platforms Create, Perpetuate, and Value Health Inequities. Med Anthropol Q. 2021;35:327.","journal-title":"Med Anthropol Q"},{"issue":"10","key":"4388_CR55","doi-asserted-by":"publisher","first-page":"e2021684","DOI":"10.1001\/jamanetworkopen.2020.21684","volume":"3","author":"SN Saleh","year":"2020","unstructured":"Saleh SN, Ajufo E, Lehmann CU, Medford RJ. A Comparison of Online Medical Crowdfunding in Canada, the UK, and the US. JAMA Netw Open. 2020;3(10):e2021684.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"4388_CR56","doi-asserted-by":"publisher","first-page":"e2026946","DOI":"10.1001\/jamanetworkopen.2020.26946","volume":"3","author":"ER Silver","year":"2020","unstructured":"Silver ER, Truong HQ, Ostvar S, Hur C, Tatonetti NP. Association of Neighborhood Deprivation Index With Success in Cancer Care Crowdfunding. JAMA Netw Open. 2020;3(12):e2026946.","journal-title":"JAMA Netw Open"},{"key":"4388_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.socscimed.2017.08.035","volume":"191","author":"MJME Renwick","year":"2017","unstructured":"Renwick MJME. Crowdfunding our health: Economic risks and benefits. Soc Sci Med. 2017;191:48\u201356.","journal-title":"Soc Sci Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04388-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:38:50Z","timestamp":1786660730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04388-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04388-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Colorado Multiple Institutional Review Board 23-1605: Not human subject research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the author(s) used ChatGPT in order to improve readability. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicole Nolen is an employee of the\n                      N\n                      \u2009=\u20091 Collaborative, a nonprofit organization discussed in this manuscript. The\n                      N\n                      \u2009=\u20091 Collaborative is referenced as one of several examples of organizations supporting individualized therapy development. Several co-authors serve in unpaid advisory or volunteer roles within the\n                      N\n                      \u2009=\u20091 Collaborative. These affiliations are non-financial in nature. All authors declare that this affiliation did not influence the analysis nor conclusions presented.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"281"}}